Will physicians use the iPhone for CME?

Share this article:
Apple has sold the iPhone to hundreds of thousands of people since its June launch. According to Manhattan Research, 75,000 physicians do CME on a PDA. Should any of them use the sleek new gadget over, say, a RIM BlackBerry?

iPhone's chief benefit may be its computer-grade Web browser, something that “doesn't set any limits on the types of media that we can integrate,” said Sandeep Shah, CEO, Skyscape.
It means any online text, image, video or audio content is accessible from pre-existing CME activities, said Steven Zatz, MD, EVP, professional services, WebMD. A Wi-Fi network in the office boosts surfing speed.

Customized medical reference content has arrived from Unbound Medicine, whose president and CEO, Bill Detmer, MD, said the iPhone, like other wireless devices, enables doctors and nurses to carry medical knowledge “wherever they roam.”

This phone offers a larger and higher-resolution screen to view it.

But Flash-enabled videos are not accessible, said Robert Stern, president/CEO, MedPage Today, which offers an iPhone page on its site and plans to support Apple's video technology in the fall.
And while iPhone is impressive, it may not supplant the one device many young hospitalists carry, the Palm Treo, said Michael Elhert, MD, president, American Medical Students Association: “All the doctors I know, it's not about e-mail; it's about their drug programs, their treatment protocols…I'm not sure how the iPhone would be unique.”

While vendors appreciate the phone's wider creative potential, and its package of features is superior, adoption by the medical community will depend on other factors, including how well it provides its core voice functionality, said Shah.

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union